Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J van Rossum

Showing results (101-110 of 147) with videos related to

Pageof 15
Sort By:
The Journal of Rheumatology|January 19, 2010
Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanerceptMarieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Cancer Epidemiology|August 22, 2012
Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccinationM Mollers, M Scherpenisse, F R M van der Klis, et al.
Arthritis Care & Research|October 20, 2019
Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System Item Banks in a Dutch Clinical Sample of Children With Juvenile Idiopathic ArthritisMichiel A J Luijten, Caroline B Terwee, Hedy A van Oers, et al.
Annals of the Rheumatic Diseases|June 16, 2009
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritisF H M Prince, M Twilt, S C M Simon, et al.
Annals of the Rheumatic Diseases|July 8, 2009
Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritisF H M Prince, L M Geerdink, G J J M Borsboom, et al.
The Journal of Rheumatology|January 17, 2018
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic ArthritisFaekah Gohar, Janneke Anink, Halima Moncrieffe, et al.
Annals of the Rheumatic Diseases|July 3, 2008
The TRAF1/C5 region is a risk factor for polyarthritis in juvenile idiopathic arthritisH M Albers, F A S Kurreeman, J J Houwing-Duistermaat, et al.
Pediatric Rheumatology Online Journal|May 10, 2024
Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trialBastiaan T van Dijk, Sytske Anne Bergstra, J Merlijn van den Berg, et al.
Pediatric Rheumatology Online Journal|August 26, 2023
Significant pain decrease in children with non-systemic Juvenile Idiopathic Arthritis treated to target: results over 24 months of follow upKatinka Spekking, Janneke Anink, Piroska de Boer, et al.
Breast Cancer Research and Treatment|August 20, 2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trialA G J van Rossum, P C Schouten, K E Weber, et al.
Pageof 15

Showing results (101-110 of 147) with videos related to

Sort By:
Pageof 15
The Journal of Rheumatology|January 19, 2010
Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanerceptMarieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Cancer Epidemiology|August 22, 2012
Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccinationM Mollers, M Scherpenisse, F R M van der Klis, et al.
Arthritis Care & Research|October 20, 2019
Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System Item Banks in a Dutch Clinical Sample of Children With Juvenile Idiopathic ArthritisMichiel A J Luijten, Caroline B Terwee, Hedy A van Oers, et al.
Annals of the Rheumatic Diseases|June 16, 2009
When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritisF H M Prince, M Twilt, S C M Simon, et al.
Annals of the Rheumatic Diseases|July 8, 2009
Major improvements in health-related quality of life during the use of etanercept in patients with previously refractory juvenile idiopathic arthritisF H M Prince, L M Geerdink, G J J M Borsboom, et al.
The Journal of Rheumatology|January 17, 2018
S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic ArthritisFaekah Gohar, Janneke Anink, Halima Moncrieffe, et al.
Annals of the Rheumatic Diseases|July 3, 2008
The TRAF1/C5 region is a risk factor for polyarthritis in juvenile idiopathic arthritisH M Albers, F A S Kurreeman, J J Houwing-Duistermaat, et al.
Pediatric Rheumatology Online Journal|May 10, 2024
Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trialBastiaan T van Dijk, Sytske Anne Bergstra, J Merlijn van den Berg, et al.
Pediatric Rheumatology Online Journal|August 26, 2023
Significant pain decrease in children with non-systemic Juvenile Idiopathic Arthritis treated to target: results over 24 months of follow upKatinka Spekking, Janneke Anink, Piroska de Boer, et al.
Breast Cancer Research and Treatment|August 20, 2017
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trialA G J van Rossum, P C Schouten, K E Weber, et al.
Pageof 15